Clinical Trial Update: PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PD-1 inhibitor with decitabine followed by autologous stem cell transplant as second-line therapy for relapsed or refractory classic Ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Or Refractory Classic Hodgkin Lymphoma

Drugs mentioned

• Decitabine (Decitabine)
• PD-1 inhibitor

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Hodgkin Lymphoma, Adult, Relapse | Phase 2 | Status: UNKNOWN